We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Countdown to TransMedics (TMDX) Q2 Earnings: Wall Street Forecasts for Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that TransMedics (TMDX - Free Report) will report quarterly earnings of $0.48 per share in its upcoming release, pointing to a year-over-year increase of 37.1%. It is anticipated that revenues will amount to $147.37 million, exhibiting an increase of 28.9% compared to the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
In light of this perspective, let's dive into the average estimates of certain TransMedics metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts forecast 'Net revenue by OCS product- OCS Lung net revenue' to reach $4.50 million. The estimate suggests a change of -4.2% year over year.
The consensus estimate for 'Net revenue by OCS product- OCS Liver net revenue' stands at $108.56 million. The estimate indicates a change of +40.9% from the prior-year quarter.
Analysts predict that the 'Net revenue by OCS product- OCS Heart net revenue' will reach $32.38 million. The estimate indicates a change of +3% from the prior-year quarter.
Analysts expect 'Geographic Revenues- United States' to come in at $142.05 million. The estimate indicates a year-over-year change of +31%.
According to the collective judgment of analysts, 'Geographic Revenues- All other countries' should come in at $4.47 million. The estimate indicates a change of -5.2% from the prior-year quarter.
TransMedics shares have witnessed a change of -17.8% in the past month, in contrast to the Zacks S&P 500 composite's +4.9% move. With a Zacks Rank #3 (Hold), TMDX is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Countdown to TransMedics (TMDX) Q2 Earnings: Wall Street Forecasts for Key Metrics
Wall Street analysts forecast that TransMedics (TMDX - Free Report) will report quarterly earnings of $0.48 per share in its upcoming release, pointing to a year-over-year increase of 37.1%. It is anticipated that revenues will amount to $147.37 million, exhibiting an increase of 28.9% compared to the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
In light of this perspective, let's dive into the average estimates of certain TransMedics metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts forecast 'Net revenue by OCS product- OCS Lung net revenue' to reach $4.50 million. The estimate suggests a change of -4.2% year over year.
The consensus estimate for 'Net revenue by OCS product- OCS Liver net revenue' stands at $108.56 million. The estimate indicates a change of +40.9% from the prior-year quarter.
Analysts predict that the 'Net revenue by OCS product- OCS Heart net revenue' will reach $32.38 million. The estimate indicates a change of +3% from the prior-year quarter.
Analysts expect 'Geographic Revenues- United States' to come in at $142.05 million. The estimate indicates a year-over-year change of +31%.
According to the collective judgment of analysts, 'Geographic Revenues- All other countries' should come in at $4.47 million. The estimate indicates a change of -5.2% from the prior-year quarter.
View all Key Company Metrics for TransMedics here>>>TransMedics shares have witnessed a change of -17.8% in the past month, in contrast to the Zacks S&P 500 composite's +4.9% move. With a Zacks Rank #3 (Hold), TMDX is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .